Expertise in
3
conditions

David Pasquier

Lille, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
3
conditions
Lille, FR 

Overview

David Pasquier practices practicing medicine in Lille, France.

Mr. Pasquier is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Breast Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Mastectomy.

He is actively involved in clinical research, co-authoring 157 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Lille, France
Other Locations
CHU de Lapeyronie
Montpellier, France
Villeneuve-d'ascq, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial
Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial
Enrollment Status: Recruiting
Publish Date: August 26, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2026
Intervention Type: Drug
Study Drugs: Association atezolizumab, BDB001
Study Phase: Phase 2
Relapse in Previously Irradiated Prostate Bed : a Phase I/II Study of Stereotactic Ablative Reirradiation Potentiated by Metformin
Relapse in Previously Irradiated Prostate Bed : a Phase I/II Study of Stereotactic Ablative Reirradiation Potentiated by Metformin
Enrollment Status: Active_not_recruiting
Publish Date: June 23, 2026
Intervention Type: Drug, Radiation
Study Drug: Metformin
Study Phase: Phase 1/Phase 2
Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Radiation
Study Phase: Not Applicable
Adjuvant Radiotherapy in Breast With Intensity Modulated by Tomotherapy: Evaluation of the Toxicity and Quality of Life
Adjuvant Radiotherapy in Breast With Intensity Modulated by Tomotherapy: Evaluation of the Toxicity and Quality of Life
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2026
Multicentre Study Evaluating the Use of a Biodegradable Balloon for the Treatment of Prostate Cancer (of Intermediate Risk) by Intensity Modulated Conformal Radiotherapy (BioPro-RCMI)
Multicentre Study Evaluating the Use of a Biodegradable Balloon for the Treatment of Prostate Cancer (of Intermediate Risk) by Intensity Modulated Conformal Radiotherapy (BioPro-RCMI)
Enrollment Status: Terminated
Publish Date: March 17, 2026
Intervention Type: Device
Study Phase: Not Applicable
An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Radiation, Drug
Study Drugs: Apalutamide, Luteinising Hormone Releasing Hormone agonist
Study Phase: Phase 3
View 6 Less Clinical Trials

157 Total Publications

Local treatment for HER2-positive or triple negative second ipsilateral breast cancer event: A propensity score-matched analysis of the GEC-ESTRO database.
Local treatment for HER2-positive or triple negative second ipsilateral breast cancer event: A propensity score-matched analysis of the GEC-ESTRO database.
Journal: Breast (Edinburgh, Scotland)
Published: June 05, 2026

Frequently Asked Questions about David Pasquier

Is David Pasquier a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. David Pasquier is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does David Pasquier participate in research or clinical trials?

Yes. David Pasquier has published 157 articles and abstracts on conditions like Prostate Cancer. You can view a list of David Pasquier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pasquier's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile